Rhythm Pharmaceuticals (RYTM) Non-Current Assets (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Non-Current Assets data on file, last reported at $12.2 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $12.2 million, down 29.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.6 million (down 40.33% YoY), and the FY2025 annual result was $13.3 million, down 26.52% from the prior year.
• Non-Current Assets retreated to $12.2 million in Q1 2026 per RYTM's latest filing, from $13.3 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $31.4 million in Q1 2022 and troughed at $12.1 million in Q2 2025.
• A 5-year average of $22.0 million and a median of $24.5 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets surged 211.41% in 2022, then sank 50.76% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $28.2 million in 2022, then declined by 13.34% to $24.5 million in 2023, then slipped by 26.16% to $18.1 million in 2024, then decreased by 26.52% to $13.3 million in 2025, then decreased by 7.94% to $12.2 million in 2026.
• Business Quant data shows RYTM's Non-Current Assets at $12.2 million in Q1 2026, $13.3 million in Q4 2025, and $12.1 million in Q3 2025.